Setmelanotide for weight loss in pseudohypoparathyroidism type 1a
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests an experimental medication called setmelanotide to see if it can help with weight loss in people who have pseudohypoparathyroidism type 1a (PHP1a), a rare genetic condition that often leads to obesity. The goal is to find a new treatment option for weight problems related to PHP1a.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of pseudohypoparathyroidism type 1a (PHP1a) with a known GNAS gene mutation.
- Your diabetes and high cholesterol are well managed with current treatments.
- You have not changed or started any medications that could affect weight or metabolism in the last 3 months.
- You do not expect to need changes to your medications during the initial treatment period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
This study tests a new medicine to see how well it helps people with excess body weight lose weight. It may be an option if you have tried to lose weight through dieting before but haven't had lasting success.
This study tests a weekly injection called tirzepatide to help people with obesity lose weight. It will be done at Hospital de Clínicas in Paraguay and lasts about 12 months.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This study tests an investigational drug called macupatide to see if it can help people with overweight or obesity lose weight. It is for people who do not have type 2 diabetes and are in generally good health.
This study tests a weekly injection called tirzepatide in people with type 1 diabetes who are overweight or have obesity. The goal is to see if it helps with blood sugar control and weight loss when added to insulin therapy.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.